Genticel and Genkyotex Announce Intention to Enter into Strategic Combination
GENTICEL REPORTS FINAL RESULTS OF GTL001 PHASE 2 TRIAL IN HPV16/18-INFECTED WOMEN
GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines
BUSINESS UPDATE - THIRD QUARTER 2016
GENTICEL PRESENTS FIRST HALF 2016 FINANCIAL RESULTS AND UPDATES ITS OPERATIONAL OUTLOOK
Disclosure of the total number of voting rights and shares composing the share capital
HALF-YEAR SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE
BUSINESS UPDATE - SECOND QUARTER 2016
GENTICEL APPOINTS EUMEDIX AS STRATEGIC ADVISOR TO SUPPORT COMPANY'S ACCESS TO INNOVATIVE DRUG CANDIDATES
GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN
GENTICEL TO PRESENT CLINICAL RESULTS OF GTL001 AND PRECLINICAL RESULTS OF GTL002 AT EUROGIN 2016 CONGRESS IN SALZBURG, AUSTRIA
GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001
GENTICEL ANNOUNCES PUBLICATION IN 'CLINICAL CANCER RESEARCH' OF PHASE 1 TRIAL RESULTS SUPPORTING SAFETY, TOLERABILITY AND IMMUNOGENICITY OF GTL001
BUSINESS UPDATE - FIRST QUARTER 2016
PUBLICATION OF THE 2015 ANNUAL FINANCIAL REPORT
PUBLICATION OF THE FIRST ISSUE OF GENTICEL'S SHAREHOLDER NEWSLETTER
GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001
GENTICEL ANNOUNCES 2015 ANNUAL RESULTS AND STRATEGIC UPDATE FOR 2016
GENTICEL UPDATES ITS FINANCIAL CALENDAR FOR 2016 AND ANNOUNCES PARTICIPATION IN KEY CONFERENCES IN H1 2016
GENTICEL REPORTS INITIAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001
BUSINESS UPDATE - FOURTH QUARTER 2015
GENTICEL ANNOUNCES ITS FINANCIAL CALENDAR FOR 2016
SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE
GENTICEL TO EVALUATE ROCHE MOLECULAR SYSTEMS' COBAS® HPV TEST IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001
Genticel appoints Rémi Palmantier, PhD, as Chief Scientific Officer to accelerate its development
Ask us your questions
Suscribe to Newsletter
